Psilocybin Just Got the FDA's Fastest Lane Ever Built. Getting There Is Still the Hard Part.

A standard FDA new-drug review takes 10 to 12 months. Under the voucher program created by Executive Order 14401, three companies are now working a review that can close in as little as one.

The fastest path an experimental drug has ever had through the FDA now runs through psychedelics, and the bottleneck moved somewhere the voucher doesn’t reach.

Signed April 18, the order directs the FDA Commissioner to award “National Priority Vouchers” to Breakthrough Therapy-designated psychedelics, compressing the review clock from 10-12 months to 1-2. Three have gone out so far: Compass Pathways for psilocybin in treatment-resistant depression, the Usona Institute for psilocybin in major depressive disorder, and Transcend Therapeutics for methylone in PTSD. CNN reported the same order directs the FDA and DEA to jointly build a Right to Try pathway for investigational psychedelics — ibogaine included — for patients who’ve run out of other options and can’t wait for approval at all.

Here’s the part that doesn’t move at voucher speed: psilocybin and methylone are still Schedule I. An accelerated FDA approval changes what the drug’s maker can eventually sell and how it gets studied — it does not, on its own, reschedule the compound, license a single new clinic to administer it, or touch the state-by-state patchwork of psychedelic-assisted therapy laws that determines whether a patient in your state can actually get a legal dose once a drug clears the FDA. Oregon and Colorado built full licensing systems from scratch after their own ballot measures. Most states haven’t started.

What that means in practice: a therapist in a state without a psychedelic-therapy framework could watch psilocybin get FDA approval next year and still have no legal way to administer it, because federal approval and state scope-of-practice law are two separate locks, and this order only turns one of them. If you or a family member is watching this space because standard depression or PTSD treatment hasn’t worked, the voucher timeline is real progress — but “FDA approved” won’t automatically mean “available near you.” Ask any clinic making that claim right now which license they’re actually operating under.